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Abstract
Biomarkers can be important predictors of disease severity and progression. The intense exposure 
to particulates and other toxins from the destruction of the World Trade Center (WTC) 
overwhelmed the lung’s normal protective barriers. The Fire Department of New York (FDNY) 
cohort not only had baseline pre-exposure lung function measures but also had serum samples 
banked soon after their WTC exposure. This well phenotyped group of highly exposed first 
responders is an ideal cohort for biomarker discovery and eventual validation. Disease progression 
was heterogeneous in this group in that some individuals subsequently developed abnormal lung 
function while others recovered. Airflow obstruction predominated in WTC exposed patients who 
were symptomatic. Multiple independent disease pathways may cause this abnormal FEV1 after 
irritant exposure. WTC exposure activates one or more of these pathways causing abnormal FEV1 
in an individual. Our hypothesis was that serum biomarkers expressed within 6 months after 
World Trade Center (WTC) exposure reflect active disease pathways and predict subsequent 
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development or protection from abnormal FEV1<lower limit of normal (LLN) known as WTC-LI. 
We utilized a nested case-cohort control design of previously healthy never smokers who sought 
subspecialty pulmonary evaluation to explore predictive biomarkers of WTC-LI. We have 
identified biomarkers of Inflammation, metabolic derangement, protease/antiprotease balance and 
vascular injury expressed in serum within 6 months of WTC exposure that were predictive of their 
FEV1 up to 7 years after their WTC exposure. Predicting future risk of airway injury after 
particulate exposures can focus monitoring and early treatment on a subset of patients in greatest 
need of these services.
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Occupational Exposure and the Development of Obstructive Airways 
Disease (OAD)
There is mounting evidence that occupational exposures are a cause of OAD.1 Occupational 
exposures are varied but often consist of particulate matter (PM) and other toxins. 
Epidemiologic evidence links PM exposure to the development of vascular and pulmonary 
diseases. 2-4 The development of OAD from PM induced inflammation and smoke is poorly 
understood,5 but studies have shown that exposure to high ambient PM significantly 
decreases forced expiratory volume over 1 second (FEV1) after 5-7 days.6,7 Long-term 
exposure to air pollutants from motor vehicles and other sources impairs lung function.8-12 
Upper respiratory symptoms increase by 3% per 10 mcg/m3 of PM exposure.6,13
WTC Particulate Matter Exposure
The destruction of the WTC led to the release of an estimated 10 million tons of material, 
exposing over 300,000 rescue workers and New York City (NYC) residents and local 
workers to WTC particulate matter (WTC-PM).14-16 The concentrations of airborne and 
respirable WTC-PM ranged from 1-100 mg/m3 immediately after the WTC collapse.17-19 
One month after the event, PM2.5 (≤ 2.5 microns) concentration was 196 mcg/m3, three 
times the National Ambient Air Quality Standards 24 hour standard.20 The toxicology and 
physical properties of WTC-PM have been well described. 18,21 WTC-PM is primarily 
composed of pulverized concrete, plastics and other hydrocarbons. WTC-PM was found to 
be highly alkaline; pH 9-11. 18,22 Exposure to both fine (PM2.5) and coarse (PM53,, >53 
microns) PM has been implicated in the development of lung injury. 23,24
Many rescue and recovery workers as well as residents and local workers continued to be 
exposed to dust for at least three months.25 Induced sputum of NYC firefighters who were 
exposed to WTC-PM post 9/11 showed increased amounts of PM (1-50μm), neutrophils, 
and eosinophils even 10 months after the original exposure.26 In a case series of 
symptomatic local residents and community workers that underwent lung biopsy several 
years after 2001, emphysematous change, and small airway abnormalities, and rare cases of 
interstitial fibrosis were seen. Furthermore, opaque and birefringent particles were found 
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within the macrophages of all cases, and particulate analysis showed these particles to be 
similar in composition to WTC particulates.27
WTC Associated Pulmonary Function and Radiographic Phenotype
Respiratory compromise has been documented in FDNY rescue workers19,28-32, other 
exposed workers 33 and lower Manhattan residents.34-36 These affected WTC exposed 
individuals continue to have increased symptoms, medication usage, pulmonary disability 
and lower quality of life 13 years after exposure.19,20,22,24,28-32,37-76 Thus far, the 
physiologic and radiographic phenotype associated with WTC exposure has been 
heterogeneous in nature, Table 1. Many exposed individuals have bronchial wall thickening 
and air trapping on CT. Emphysema, COPD, and OAD occur, but some studies have shown 
that there is a significant restrictive phenotype seen.
The Utility of Biomarkers of Occupational Lung Function Loss
Identification of biomarkers of disease progression is crucial to guide early intervention as 
well as treatment. In addition, identification of biomarkers of disease has potential to direct 
future research into mechanisms producing airflow obstruction. These biomarkers can also 
identify those at risk who would most benefit from avoidance of further exposure or 
aggressive management. Measuring biomarkers in serum is a powerful and cost effective 
approach for risk factor discovery. Immediately after 9/11, the FDNY-Bureau of Health 
Services (BHS) began implementing protocols for obtaining, processing, storing and 
retrieving serum from the WTC-exposed firefighters. This cohort of nearly 16,000 Fire 
Department of New York (FDNY) rescue workers (firefighters, paramedics and emergency 
medical technicians) form a well-characterized cohort that has been a powerful resource for 
documenting the impact of WTC exposure on the lung, Figure 1. Serum samples were 
obtained on a majority of the cohort from September, 2001 to February, 2002, at initial 
development of airflow obstruction. Taking advantage of this unique cohort, our group has 
investigated predictive biomarkers of WTC-associated lung injury.77-79 We have identified 
biomarker subtypes that may be indicators of associated pathways active in the development 
of WTC associated end-organ dysfunction. This paper is dedicated to reviewing our findings 
and their physiologic importance.
For biomarker discovery, we chose to focus on FEV1 as outcome and indicator of disease 
state. Spirometry had been measured annually in the FDNY cohort three years prior to 
9/11/2001, and this cohort continued to receive annual pulmonary function tests (PFTs) as 
part of the FDNY-WTC-Medical Monitoring and Treatment Program (MMTP). This 
longitudinal surveillance allowed us to document that in the first year after 9/11, there was a 
decline in FEV1 in exposed FDNY rescue workers at a rate twelve times greater than that 
found pre-9/11.29,80 Further evaluation showed that firefighters who had never smoked lost 
an average of 439 mL of FEV1 in the first year post-9/11, followed by a mean annualized 
reduction in FEV1 of 26 mL per year in the subsequent 6.5 years.19,66 In addition, acute 
airway inflammation, reactive airway dysfunction, and overall decline in FEV1 have been 
reported in rescue workers exposed to WTC-PM.31,67
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Our study cohort demonstrated a reduced FEV1 below the lower limits of normal (LLN) was 
consistent with an obstructive pattern67,81 with a low FEV1/FVC ratio (median 72, IQR 
65-77). This suggested that FEV1<LLN could be used as a surrogate for obstruction in this 
population. We therefore defined WTC-Lung Injury (WTC-LI) in this population of 
firefighters by their FEV1<LLN measured during subspecialty visit after exposure and upon 
becoming symptomatic. Measurement of FEV1 is robust and easily measurable. 
Furthermore, FEV1 has been the primary endpoint in trials of therapeutic agents and has 
been used to track health outcomes in numerous lung diseases, including chronic obstructive 
pulmonary disease (COPD). 82
Design of the FDNY-WTC Biomarker Study
At their first FDNY medical monitoring exam (MME) post-9/11, all participants received 
PFT and serum aliquots were collected and deposited in a biorepository, Figure 1. 
Symptomatic firefighters were referred to subspecialty pulmonary evaluation between 
9/12/2001 and 3/10/2008.83
Nested Case-Cohort Control Study Design
We used a nested case-cohort control strategy to define biomarker expression, Figure 1.84-87 
The baseline cohort was derived from 1,720 exposed workers who needed subspecialty 
pulmonary evaluation and treatment within 6.5 years of 9/11. There was significant inter-
individual variation in lung function with some patients recovering and others suffering loss 
of lung function thereby allowing us to study both outcomes in a similarly exposed 
cohort.46,88 A homogeneous sub-cohort of subjects without prior lung disease or tobacco use 
was identified after applying inclusion criteria (n=801). The two case subgroups (n=100 for 
each) were intended to over-sample those susceptible and resistant to WTC-LI. Those 
susceptible to WTC-LI had FEV1<LLN and included patients in the bottom octile of 
FEV1% predicted at the time of sub-specialty pulmonary exam. In contrast, the resistant 
population included those identified in the top octile of FEV1% predicted at the same time 
point, and had FEV1≥LLN. The cohort (n=801) was stratified on tertiles of FEV1 and BMI, 
and the cohort control (n=171) was randomly selected. This cohort control has overlapping 
populations with the susceptible and resistant populations, and ensures sufficient 
representation of the general FDNY population. All subjects signed informed Institutional 
Review Board-approved consent at the time of enrollment allowing analysis of their 
information and samples for research (Montefiore Medical Center; #07-09-320 and New 
York University; #11-00439). Serum samples were analyzed utilizing Luminex as 
previously described. 40,50 Both case definitions and cohort-controls were randomized to 
batches in a 1:1:2 ratio to avoid batch effect bias and analyzed contemporaneously to avoid 
variability in time dependent sample decay. 85,89
All demographics were obtained from the FDNY-WTC-monitoring database. Degree of 
exposure was self-reported at the first FDNY-WTC-monitoring and was categorized using 
the FDNY-WTC Exposure Intensity Index based on Arrival Time: 1. Present on the morning 
of 9/11/2001 2. Arrived between the afternoon of 9/11/2001 and 9/12/2001.67 Those arriving 
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after day three were excluded from analysis as a result of their low numbers in this 
sample.49,90
Serum Biomarkers of WTC-LI
Biomarkers of Inflammation
We hypothesized that individuals susceptible to airflow obstruction, induced by 
environmental irritants, would express different levels of pro-inflammatory cytokines 
compared to similarly exposed individuals in the cohort-control., We identified 
inflammatory cytokines and chemokines in the serum of FDNY rescue workers obtained 
within six months of 9/11 using commercially available multiplex kits, Figure 1. We 
correlated inflammatory biomarkers at monitoring entry with FEV1 at sub-specialty 
pulmonary exam. Cases of those susceptible to WTC-LI with FEV1<LLN were compared to 
controls with FEV1≥LLN. From monitoring entry to sub-specialty pulmonary exam years 
later, FEV1 declined 12% in cases and increased 3% in controls. Elevated Granulocyte 
Macrophage-Colony Stimulating Factor (GM-CSF) and Macrophage Derived Chemokine 
(MDC) increased the risk for subsequent FEV1<LLN by 2.5 fold and 3.0 fold in a logistic 
regression model adjusted for exposure, BMI, age on 9/11, and neutrophil, Figure 2A. Roles 
for GM-CSF and MDC in airway injury are biologically plausible in that human bronchial 
epithelial cells produce GM-CSF in response to PM and MDC is elevated in 
bronchoalveolar lavage of asthmatics. The model had sensitivity of 38% and a specificity of 
88%. The low sensitivity suggested other biomarkers not yet identified were significant risk 
factors for accelerated decline of lung function after irritant exposure at the WTC site.
Metabolic Biomarkers as Predictors of WTC Lung Function Loss
Metabolic syndrome (MetSyn) is a principal contributor to systemic inflammation 
associated end organ damage. 91 This interaction is best understood in vascular diseases, but 
previous cross sectional studies have suggested associations of impaired lung function with 
MetSyn. 92-96
Utilizing our case-cohort control study design, we diagnosed MetSyn using World Health 
Organization (WHO)-modified National Heart Lung and Blood Institute/American Heart 
Association criteria. Subjects had to meet three of the following five criteria: i. Elevated 
triglycerides ≥150 mg/dL (1.7mmol/L). ii. Reduced High Density Lipoprotein (HDL)<40 
mg/dL in men iii. Elevated systolic blood pressure (BP) ≥130 mm Hg or diastolic BP ≥85 
mm Hg iv. Elevated fasting glucose ≥100 mg/dL.97,98 v. Body Mass Index (BMI) >30 was 
substituted for increased waist circumference as per WHO Criteria. 99 Concurrent fasting 
blood levels of HDL, Glucose, and triglycerides were assayed when the subjects’ first 
post-9/11 serum samples were collected and banked at monitoring entry.
We found that cases of WTC-LI had significantly higher glucose and heart rate at 
monitoring entry than controls. However, cases did not have significantly different 
triglycerides, systolic blood pressure, or HDL. There was a trend of a higher percentage of 
individuals with MetSyn in cases compared to controls (27% vs 16%, p=0.07). Cases had a 
larger proportion of individuals with higher glucose (28% vs 16%, p=0.03) and lower HDL 
(32% vs 20%, p=0.05). The differences in lipid profiles between cases and controls were 
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accentuated when individuals had combined abnormalities in triglycerides and HDL 
(dyslipidemia, defined as triglycerides≥150mg/dL and HDL<40mg/dL) (28% vs 14%, 
p=0.006). In addition, we defined a heart rate above the median of 66 beats per minute 
(bpm) as elevated for the entire nonsmoking cohort. Cases compared to controls had a larger 
proportion with elevated heart rate (65% vs 48% p=0.02). We then defined cut points for 
metabolic analytes using the top quartile for leptin and amylin.
We assessed if any of the biomarkers with significantly different prevalence altered the odds 
ratio (OR) of being a case using logistic models adjusted for BMI, age on 9/11, race and 
WTC arrival time. When biomarkers and clinical parameters were included in the final 
model, dyslipidemia, elevated heart rate and elevated leptin significantly increased the odds 
of being a case: Dyslipidemia, OR=3.03 , heart rate≥66 bpm, OR=2.20 and leptin ≥ 10,300 
pg/mL OR=3.00, Figure 2A. Elevated amylin was strongly protective, decreasing the odds 
of being a case by 84%, Figure 2A. We assessed the ability of the final logistic regression 
model to predict case status using receiver operating characteristic (ROC) analysis. The final 
model had an area under the curve (AUC) of 0.774 after adjusting for previously mentioned 
covariates.
Biologically active lipid metabolites are biologically plausible pathways of disease and can 
be attenuated pharmacologically. As a logical extension of our earlier work we therefore 
turned our attention to Lysophosphatidic acid (LPA), an LDL derivative and Apolipoprotein 
(Apo)A1, a component of HDL. LPA activates pathways involved in vascular injury.100-103 
Vascular injury occurs early in smoking related COPD with pulmonary perfusion 
abnormalities and reduced blood return to the heart observed prior to development of 
abnormal FEV1.104,105 Similar pathophysiology likely occurs in irritant induced COPD. 
Pulmonary arteriopathy was present in 58% of lung biopsies from non-FDNY WTC-PM 
exposed individuals and in 74% with constrictive bronchiolitis after inhalational exposures 
suffered during military service in Iraq and Afghanistan.27,106.
To assess the relationship between LPA and ApoA1 with the outcome of being a susceptible 
case, we used a multivariable logistic model (adjusted for BMI, exposure intensity, pre-9/11 
FEV1% predicted, age on 9/11, race, WTC exposure, dyslipidemia, platelet and neutrophil 
count). In the adjusted model, a 10 μM increase of LPA was associated with a 14% increase 
in the odds of having WTC-LI while an increase of 1 mg/mL of ApoA1 increased the odds 
of developing WTC-LI by 29%. These findings further demonstrate the biological relevance 
of lipids and their metabolites in the progression of OAD after WTC exposures.
Vascular Biomarkers of WTC-LI
Recent studies associate systemic vascular involvement with lung disease.107,108 
Prospective studies have demonstrated an association between systemic inflammation, 
impaired lung function, and central arterial stiffness that occurs prior to the development of 
cardiovascular disease (CVD).109-111 Similarly, perfusion abnormalities and reduced 
pulmonary blood flow occur prior to development of abnormal FEV1 in smokers at risk for 
COPD. Lung biopsies from WTC-PM exposed individuals showed pulmonary arteriopathy 
and constrictive bronchiolitis secondary to inhalational exposures, and hinted at the potential 
use of vascular biomarkers associated with WTC-LI.27,106
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Vascular biomarkers were investigated in subjects that went on to develop WTC-LI and in 
those that did not. Individuals with elevated Apolipoprotein (Apo)AII and C-reactive protein 
(CRP) levels within six months of 9/11 had significantly increased risk of developing 
decreased lung function over the subsequent six years while elevated Macrophage 
Inflammatory Protein (MIP-4) reduced the risk of susceptibility to decreased lung function, 
Figure 2A. Alternately, firefighters with elevated soluble Vascular Cell Adhesion Molecule 
(sVCAM) and low myeloperoxidase (MPO) levels within six months of 9/11/2001 predicted 
recovery of lung function, and showed return of FEV1 to pre-9/11 values after an acute 
decline post-9/11, Figure 2B.
The biologic plausibility of our findings is significantly supported by the literature. CRP is a 
known marker of acute systemic inflammation and CVD that has been shown to have an 
inverse relationship with FEV1.112-114 CRP levels were elevated in individuals with COPD 
independent of any CVD risks.115 Pulmonary hypertension, a disease of the pulmonary 
vasculature, is associated with CVD biomarkers such as apolipoprotein.116 This parallels our 
prior observation that dyslipidemia predicts poor outcome after WTC dust exposure.
Macrophage inflammatory protein-4 (MIP-4) was inversely associated with odds of 
developing WTC-LI. This finding contrasts with that of the Evaluation of COPD 
Longitudinally to Identify Predictive Surrogate Endpoints (ECLIPSE) cohort, in which 
elevated MIP-4 was associated with concurrent COPD, increased risk of cardiovascular 
hospitalization and mortality.117 The difference in the association of of MIP-4 may be due to 
the timing of the biomarker studies; our cohort had blood biomarkers prior to disease 
presentation, whereas the ECLIPSE study focused on end-stage disease. MIP-4 (CCL18, 
PARC) is an early promoter of regulatory T-cell differentiation and may generate an anti-
inflammatory counter-regulatory response that leads to protection of lung injury in our 
group.118,119 Finally, low levels of MPO demonstrate less neutrophil activation, an 
important mediator of PM-induced pulmonary and cardiovascular injury. In our group, it 
was associated with resistance to the damaging effects of WTC-PM exposure.120,121 Our 
data and other recent reports emphasize the need to better understand the mechanisms by 
which inhaled irritants damage pulmonary vessels.
In addition to serum biomarkers of vascular involvement, our group and others have 
investigated quantifiable vasculometric changes associated with OAD. An increased ratio of 
the pulmonary artery to aorta (PA/A) diameter measured by computed tomography (CT) has 
been associated with pulmonary hypertension and poor outcomes in various disease states. 
The elevated PA/A ratio implies relative pulmonary vascular enlargement and has been 
associated with past and future exacerbations in patients with moderate-to-severe COPD.122 
PA/A has been associated with a decreased FEV1 in the same population. Furthermore, in 
subjects with CVD a PA/A ratio >1 has been associated with increased mortality.123 PA/A 
from chest CT scans obtained for clinical indications in our case cohort control population 
were calculated. Using the Youden index, a PA/A value of 0.92 was selected as the cutoff 
for best predicting the development of WTC-LI in a logistic regression analysis. After 
adjusting for age at CT, pre-9/11 FEV1, BMI at sub-specialty pulmonary evaluation and 
exposure, the odds of having World Trade Center Lung Injury in patients with a value of 
PA/A ≥0.92 was 4.02, Figure 2.
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In the ECLIPSE/COPD Gene cohort, PA/A >1 was associated with disease severity and 
subjects had more advanced disease than in the FDNY-WTC cohort.122 Although our 
cohort’s mean PA and A were similar to those measured in ECLIPSE/COPD Gene cohort, 
81% of our cohort did not meet GOLD COPD criteria. Therefore, it was expected that the 
PA/A would be less than previously reported ratios of 1.122 When comparing our cohort to 
the Framingham Heart Study, our case mean PA/A and PA values are similar to their 90th% 
upper limit of normal. 124 Our study suggests that the PA/A ratio≥0.92 may represent a 
marker of early vascular injury in particulate matter related lung disease and is in line with 
these recent publications.
Protease/ Antiprotease Balance as Biomarkers of WTC-LI
The balance of protease/anti-protease activity is the crux of many diseases including 
cigarette-induced chronic lung disease and other causes of accelerated lung function 
decline.125-128 The serine antiprotease α-1 Antitrypsin (AAT) predicts accelerated FEV1 
decline in WTC exposed firefighters and is a well-studied biomarker of smoking associated 
lung disease.129 To determine the impact of AAT levels on FEV1 decline after WTC 
exposure, AAT levels and genotype were assayed were assayed in 90 randomly selected 
subjects. The rate of FEV1 loss increased with increasing AAT deficiency defined either by 
genotype or serum concentration. Moderately (MS or SZ genotype) deficient rescue 
workers’ FEV1 declined 110cm3/year more than normal, while mildly (MS or SS genotype) 
deficient rescue workers lost 32cm3/year more than normal. Rescue workers with AAT 
serum levels below 20 μmol/l lost 49 cm3/year of FEV1 compared to workers with AAT 
levels greater than or equal to 20 μmol/l. There was no impact of AAT levels or genotype on 
spirometric decline rates prior to 09/11/2001 suggesting an interaction between low AAT 
and WTC exposure.130 In data previously unreported, utilizing our case-cohort control study 
we found that AAT <85 mg/dL increased the risk of developing WTC-LI, Figure 2A.131-133
Matrix metalloproteinases (MMPs) can catabolize and degrade the extracellular matrix. 134 
Many are known intermediates of each other, and their levels are affected by environmental 
factors such as hypoxia, inflammation and oxidative stress. Several MMPs can be either 
directly inhibited by or form complexes with TIMPs. MMP/TIMP balance is another well-
defined mediator of COPD. 134
Genetic association studies with MMPs demonstrate a strong association with the 
development of lung disease.125 MMP-1 is induced in smokers with COPD and its 
overexpression in mice causes emphysema.135,136 The destructive effects of MMPs are 
inhibited by tissue inhibitors of matrix metalloproteinases (TIMPs). There is little data on 
the role of MMPs and TIMPs in the resistance to the damaging effect of dust 
exposure.137-140 One carefully done pathologic study demonstrated increased MMP-2 and 
TIMP-1 mRNA expression in surgically removed lung and predicted improved FEV1 in 
COPD patients.141 As serum MMP and TIMP expression is related to the development of 
COPD, the link between serum MMP/TIMP balance and lung function in the WTC exposed 
cohort became the focus of our next set of investigations.142
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In investigating susceptible cases, elevated serum levels of MMP-3 and MMP-12 reduce the 
risk of developing WTC-LI. Increased time between 9/11 and blood draw is associated with 
a diminished protective effect. Specifically, early elevated expression of MMP-3 and 
MMP-12 in serum within 200 days after WTC exposure predicts protected lung function 
over the subsequent seven years (2001-2008). We found that MMP-3 and MMP-12 ranges 
of the cohort were comparable to other published patient populations, including healthy 
controls and patient cohorts with emphysema or rheumatoid arthritis.143,144 MMP-3 was 
found to be more protective than MMP-12, Figure 2A. Both biomarker models displayed 
robust predictive ability by logistic regression with AUC>0.8.
Compared to susceptible cases, the resistant cases had greater than average reduction in 
FEV1 immediately after exposure, but returned to pre-exposure FEV1 over the next 6.5 
years. Because serum was drawn well before the pulmonary function test that demonstrated 
recovery, the biomarker information reflected evolving injury. All subjects in this nested 
case control investigation had heavy WTC dust exposure and arrived at the collapse site 
within 2 days of 9/11/2001. MMP-2 and TIMP-1 expression above the 75th percentile are 
protective biomarkers, significantly increasing the odds of resistance between 4.2 and 5.4 
fold. Alternately, elevated MMP-1 is a risk factor, reducing the odds of resistance by 73%, 
Figure 2B. The biomarker model using serum MMP-1, MMP-2 and TIMP-1 concentration 
predicted resistance with a sensitivity of 74%, a specificity of 86% and a receiver operator 
characteristic of 0.90. 40
Innate and Humoral Mediators
The ratio of FEV1/Forced Vital Capacity (FVC) is another well-validated spirometric 
measure of airflow obstruction. Genome wide association studies (GWAS) observed that a 
set of genetic variants of chitinases are associated with only FEV1. Polymorphisms at other 
loci can predict FEV1/FVC and both FEV1 and FEV1/FVC.145,146 Biomarkers predicting 
abnormal FEV1/FVC may therefore be distinct from those predicting abnormal FEV1. 
Hence, we investigated if biomarkers expressed within 6 months of 9/11/2001 predicted 
future abnormal FEV1/FVC in this WTC exposed cohort. In this investigation, we evaluated 
innate and humoral mediators. We found that increased serum chitotriosidase (CHIT) 
reduces the odds of developing obstruction after WTC-particulate matter exposure and is 
associated with recovery of lung function. Alternately, elevated Immunoglobulin E (IgE) 
was a risk factor for airflow obstruction and progressive lung function decline.
CHIT belongs to the glycosyl hydrolase 18 gene family that binds and cleaves chitin. CHIT 
is part of the innate host defense against bacterial and fungal infections since chitin is a 
major structural component in bacteria, fungi, insects and crustaceans.147-151 CHIT is 
produced in mature monocyte-derived macrophages, lung macrophages and other specific 
subsets of tissue macrophages. 152-155 Elevated chitotriosidase expression is associated with 
smoking induced and fibrotic lung disease. 156,157 However, its biological function has not 
been clearly defined.
IgE-mediated humoral immunity is another important immune response mechanism in the 
respiratory tract. 158 Elevated IgE is a key immune mediator in asthma. Children and adults 
with asthma have higher IgE than normal controls and anti-IgE antibody is an effective 
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asthma modulator. 159-162 Elevated serum IgE is strongly associated with low FEV1/FVC in 
patients with chronic obstructive lung disease. 163
SUMMARY
Identification of serum biomarkers that predict lung disease can direct future research into 
mechanisms producing airflow obstruction, fuel future work about their downstream effects, 
aid in the development of diagnostic markers and potential therapeutic targets in clinical 
trials. Our study cohort, with clinical information before and after a significant 
environmental exposure, serves as a unique opportunity to identify biomarkers associated 
and predictive of lung and vascular disease. Although many studies have focused on 
occupational biomarker identification, our study cohort has lung function assessment prior 
to exposure and development of disease. This is ideal for the study of predictive biomarkers, 
and has allowed us to establish leadership in pathophysiologic investigation of WTC-
LI.77-79
We have developed a high-dimensional dataset that includes at least 130 serum and 
radiographic biomarkers in a cohort of firefighters with intense exposure to World Trade 
Center dust. We have identified multiple biomarkers of biologically plausible pathways that 
are active in the development of WTC-associated end-organ dysfunction. It was necessary to 
develop a parsimonious biomarker model that would generate reproducible and 
generalizable findings. To optimize identification of candidate biomarkers from a relatively 
small sample size we utilized a case cohort control for much of our work. Furthermore, the 
small sample size in a high-dimensional biomarker dataset could obscure potential pathways 
of interest, we studied biomarkers in separate but often related pathways to further optimize 
signal to noise. Future work will include repeated serum sampling to add a longitudinal 
component to the FDNY-NYU biorepository. This will expand our understanding of 
biomarker evolution and will be a resource for investigating other long latency WTC related 
diseases.
Development of OAD following particulate matter exposure is a major health concern 
worldwide. First responders and the military may be specifically more affected by the high 
amounts of particulate exposure during disasters and conflict. Identifying predictive 
biomarkers of FEV1 loss allows for early identification of at risk individuals allowing for 
early screening, necessary treatment and risk avoidance. While unique in many ways, the 
exposures on 9/11/2001 have allowed us to make observations related to lung disease 
progression that may translate to other occupationally and environmentally exposed 
populations. The processes initiated by WTC exposure impacted multiple distinct injury and 
repair pathways. Our prior studies and this review emphasize the utility of serum stored in 
the aftermath of a disaster. The insight into protein expression in OAD gained from the 
analysis of this serum has the potential to guide future mechanistic and therapeutic studies 
designed to blunt the impact of the worldwide COPD epidemic.
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AUC Area under the curve
BHS Bureau of Health Services
BMI Body Mass Index
BP Blood Pressure
BPM Beats per Minute
BWT Bronchial Wall Thickening
CHIT Chitotriosidase
COPD chronic obstructive pulmonary disease
CVD Cardiovascular Disease
DLCO Diffusion Capacity of the Lung for Carbon Monoxide
Dyslipidemia HDL<40 mg/dL and Triglycerides≥150 mg/dL
ECLIPSE Evaluation of COPD Longitudinally to Identify Predictive Surrogate 
Endpoints
FDNY Fire Department of New York
FEV1 Forced Expiratory Volume in one second
FVC Forced Vital Capacity
GM-CSF Granulocyte Macrophage-Colony Stimulating Factor
GOLD Global Initiative for Chronic Obstructive Lung disease
GWAS Genome wide association studies
HDL High Density Lipoprotein
IgE Immunoglobulin E
IL-6 Interleukin-6
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LLN Lower Limit of Normal as defined by NHANES III
LPA Lysophosphatidic acid
MDC Macrophage Derived Chemokine
MetSyn Metabolic Syndrome
MME Medical Monitoring Exam
MIP-4 Macrophage Inflammatory Protein
MMP Matrix metalloproteinases
MMTP Medical Monitoring Treatment Program
MPO Myeoloperoxidase
NAAQS National Ambient Air Quality Standards
NHANES National
NYC New York City
NYPD New York Police Department
NYU New York University
OAD Obstructive Airways Disease
OR Odds Ratio
PA/A Pulmonary Artery/Aorta
PFT Pulmonary Function Test
PM Particulate Matter
sRAGE soluble Receptor for Advanced Glycation End Products
ROC Receiver Operator Characteristics
sVCAM soluble Vascular Cell Adhesion Molecule
TIMP tissue inhibitors of matrix metalloproteinases
TLC Total Lung Capacity
TNF-α Tumor Necrosis Factor-alpha
WHO World Health Organization
WTC World Trade Center
WTC-LI World Trade Center-Lung Injury
WTC-PM World Trade Center-Particulate Matter
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Figure 1. WTC-FDNY Biomarker Timeline and development of Nested Case- Cohort Control 
Study Design
Summary of phenotyping that was done on the cohort and case susceptible and resistant to 
WTC-LI are shown in the inclusion criteria to develop the baseline cohort. Overlapping of 
cohort control with cases susceptible and resistant to WTC-LI is highlighted in the dashed 
red circle.
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Figure 2. Overview of Biomarkers predicting WTC-LI as defined by FEV1 < LLN
A. Utilizing a Susceptible case-cohort control design B. Utilizing a resistant case-cohort 
control design. *Represents relative risk †Not previously published
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